Pfizer is shaking up its corporate structure again as it prepares to merge with Allergan and further lays the groundwork for a potential split in a few years. The structural rejig pushes out Geno Germano, who has been leading Pfizer's global innovative pharma business, and elevates one top Allergan manager, Bill Meury, to the combined company's commercial leadership team.
In this week's Chutes and Ladders, Marc Tessier-Lavigne was named president of Stanford University, Katie Wilson was named EVP of human resources at Gilead, and Osiris CEO Lode Debrabandere stepped down. Plus more hirings and retirings throughout the industry.
Sanofi is starting its latest round of job cuts with more than 500 in its home country. According to media reports, almost 300 open R&D jobs won't be filled, with another 250-plus cuts hitting Sanofi's commercial operations and corporate offices.
John Martin, the man who led Gilead Sciences from the basements of biotech to the verge of Big Pharma, is stepping down after 20 years, with longtime lieutenant John Milligan in line to take his place.
In this week's Chutes and Ladders, Michael Ball will run Novartis' Alcon unit, John Martin is stepping down as Gilead CEO, and Gary Zieziula was named president and managing director of EMD Serono. Plus more hirings and retirings throughout the industry.
Valeant's pneumonia-stricken CEO, J. Michael Pearson, is on the mend, according to a letter he penned to his colleagues on Monday. But as to when he'll be back at work, it's still up in the air.
In this week's Chutes and Ladders, Rohan Palekar was appointed CEO of Avanir Pharmaceuticals, Allan Shaw was named CFO at Syndax, and Dr. Craig Granowitz was named chief medical officer at Amarin. Plus more hirings and retirings throughout the industry.
In this week's Chutes and Ladders, Celgene named Mark Alles as CEO, Baxalta CEO Ludwig Hantson will leave following the Shire merger, and MannKind appointed Matthew Pfeffer as CEO. Plus more hirings and retirings throughout the industry.
Celgene's Mark Alles will join biopharma's slate of new CEOs in March as part of a management reshuffling at the $9 billion-plus biotech. Current chief Bob Hugin, who has led Celgene through a major expansion over the past 5 years, will move upstairs to the executive chairman's office.
A new management structure at Mumbai-based Cipla promises a high-stakes effort to help the Indian drugmaker abroad after an active spurt of acquisitions in 2015 as well as management shuffles.